The two-year, non-exclusive commercial software licensing agreement allows Phenix to use ResAppDx-EU in their telehealth smartphone app within Australia from 1 July 2020. The per test license fee received by ResApp is in the previously targeted range of $5 to $10. The licence may be extended beyond the initial two-year term by mutual agreement and either party may terminate the licence by providing 60 days written notice.
NICE
Ann: Phenix and ResApp Sign Software Licensing Agreement, page-2
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #